A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Clinical trial NCT07095452 · RECRUITING
Trial details
- NCT number
- NCT07095452
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-08
- Primary completion
- 2042-01-01
- Enrollment
- 660
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.